title: [Multicenter double-blind clinical trial comparing sucralfate vs placebo in the prevention of diarrhea secondary to pelvic irradiation].
abstract: BACKGROUND
  Sucralfate has been used in the prophylaxis of acute enteric toxicity induced by radiation therapy of pelvic organs. The aim of the study was to demonstrate the efficacy of sucralfate in the prevention of the acute enteric toxicity induced by pelvic irradiation in cancer patients, compared with placebo, in a multicentric double-blind randomised clinical trial.
  
  
  METHODS
  One hundred and twenty patients, with a localised pelvic cancer, 18 to 80 years old, with a Karnofsky index of 80% or more, and "normal" defecation habits (3-10 defecations/week), undergoing whole pelvic irradiation, were included. The duration of the study was 7 weeks, with weekly controls. The first week all patients received placebo. In the second week the patients were randomised into two groups: sucralfate (61 patients, 2 g/tid p.o. before meals) and placebo (59 patients). Radiotherapy started at the beginning of the third week and lasted until the end of the study. All patients received 45-50 Gy total dose (1.8-2 Gy/day, 5 days/week) with the "box technique". The main variables were the number of stools per week and the number of loperamide pills per week.
  
  
  RESULTS
  The number of stools per week showed no differences between groups. By the contrary in the group intention to treat (120 patients) and per protocol (100 cases) the percentage of diarrhoeal stools per week showed a statistical significance in favour of sucralfate: (p < 0.05) and (p < 0.03) respectively, concerning the evolution of this variable from the baseline (first week) to the end of the pelvic radiotherapy (seventh week). Furthermore, the consumption of loperamide was significantly lower in the sucralfate group (p < 0.001).
  
  
  CONCLUSIONS
  Sucralfate is effective in the preparation of acute enteric toxicity induced by pelvic irradiation.
authors.affiliation: Servicio de Radioterapia, Hospital de l'Esperança, Barcelona.
authors.forename: A
authors.initials: A
authors.lastname: Valls
authors.forename: I
authors.initials: I
authors.lastname: Pestchen
authors.forename: C
authors.initials: C
authors.lastname: Prats
authors.forename: J
authors.initials: J
authors.lastname: Pera
authors.forename: G
authors.initials: G
authors.lastname: Aragón
authors.forename: M
authors.initials: M
authors.lastname: Vidarte
authors.forename: M
authors.initials: M
authors.lastname: Algara
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000930:Antidiarrheals / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D004311:Double-Blind Method; D016889:Endometrial Neoplasms / Q000532:radiotherapy; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008139:Loperamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000532:radiotherapy*; D010919:Placebos; D011471:Prostatic Neoplasms / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D013392:Sucralfate / Q000627:therapeutic use*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy
chemical_list: D000930:Antidiarrheals; D005765:Gastrointestinal Agents; D010919:Placebos; D013392:Sucralfate; D008139:Loperamide